Overview

DexmedetOmidine Complement Treats Chronic insOmnia and Improves Circadian Rhythm (DOCTOR)

Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
0
Participant gender:
All
Summary
It has been reported that dexmedetomidine, alpha-2 adrenoceptor agonist, can activate endogenous neural sleep pathways in the central nervous system. This randomised, double-blinded and controlled trial was designed to investigate whether dexmedetomidine can improve/treat chronic insomnia patients. Its effects on sleep quality and improvement, EEG and circadian rhythm, brain connectivity, cognition and biomarker changes are determined.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Ruijin Hospital
Treatments:
Dexmedetomidine
Criteria
Inclusion Criteria:

- Age between 30- 65 years old

- Body mass index (BMI) between 18 and 35 kg/m^2ï¼›

- Clinical diagnosis of chronic insomniaï¼›

- Must be able to communicate with site personnel

Exclusion Criteria:

- Clinical diagnosis of mental disorders;

- Pregnancy;

- Current use of psychotropic drug ;

- Clinical diagnosis of neurological diseases